Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition.
about
Oxidative Stress Signaling in Alzheimers DiseaseAmyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activityDysfunction of amyloid precursor protein signaling in neurons leads to DNA synthesis and apoptosisc-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's DiseaseRole of redox signaling in neuroinflammation and neurodegenerative diseasesFoxO3a is activated and executes neuron death via Bim in response to β-amyloidBag1-L is a phosphorylation-dependent coactivator of c-Jun during neuronal apoptosis.Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease.XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study.Ras and Rap signaling in synaptic plasticity and mental disorders.Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease.The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing miceREGION-SPECIFIC NEURON AND SYNAPSE LOSS IN THE HIPPOCAMPUS OF APPSL/PS1 KNOCK-IN MICEOverexpression of matrix metalloproteinase-9 (MMP-9) rescues insulin-mediated impairment in the 5XFAD model of Alzheimer's diseaseDNA-PK and P38 MAPK: A Kinase Collusion in Alzheimer's Disease?p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer's diseaseN-cadherin regulates p38 MAPK signaling via association with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer diseaseBeta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.Are there roles for brain cell senescence in aging and neurodegenerative disorders?The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide.Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis.Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.Inhibiting p38 mitogen-activated protein kinase attenuates cerebral ischemic injury in Swedish mutant amyloid precursor protein transgenic mice.Lipopolysaccharide-induced tau phosphorylation and kinase activity--modulation, but not mediation, by corticotropin-releasing factor receptors.c-Jun N-terminal kinase regulates soluble Aβ oligomers and cognitive impairment in AD mouse model.GSTT1 is upregulated by oxidative stress through p38-MK2 signaling pathway in human granulosa cells: possible association with mitochondrial activity.Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.Interaction of ASK1 and the beta-amyloid precursor protein in a stress-signaling complex.5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.3,5,4'-trihydroxy-6,7,3'-trimethoxyflavone protects against beta amyloid-induced neurotoxicity through antioxidative activity and interference with cell signalingLoss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease.Hippocampal Injections of Oligomeric Amyloid β-peptide (1-42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway.In vitro and in vivo neuroprotective effects of cJun N-terminal kinase inhibitors on retinal ganglion cells.p53-dependent SIRT6 expression protects Aβ42-induced DNA damage.Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664.p38 MAPK Inhibition Improves Synaptic Plasticity and Memory in Angiotensin II-dependent Hypertensive MiceThe influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence.Alpha 1-Antichymotrypsin, an Inflammatory Protein Overexpressed in the Brains of Patients with Alzheimer's Disease, Induces Tau Hyperphosphorylation through c-Jun N-Terminal Kinase Activation.
P2860
Q22241327-93135B73-6DD9-487A-9F18-DA293E40D50AQ24556621-FD9FF563-6BEF-4FAA-B54B-1FBA4FE8BC11Q24675369-09FCCAE7-E116-4567-8388-C84786226C43Q26770431-C7975D23-B901-4D83-9A7E-E3B41DC2F532Q27012569-21281CC9-4775-4574-A113-A23E090E1336Q28570206-D33824FC-9D63-4296-BD83-360A512D4D82Q28589005-E363202A-43D7-4CE6-8FA5-DA8A0ACD6193Q28592890-4FDF877B-ECB2-4594-B657-DCCFE183DAC6Q30423728-282A5EC9-DCB7-4855-979F-0F9D46D8DF08Q30431817-87E26F6D-4B7C-4CDF-B467-770AF78884C3Q30437355-12834B3A-2523-4A7C-B406-B23E381C9203Q33393902-A7E5B530-43E9-4536-8302-DCF3EA597102Q33505668-E36EA5EA-2ABA-4A27-BF8C-C59124242E48Q33598997-51D70CB6-7E89-412B-B966-2A56E3B98571Q33677609-B172D147-5412-4C6F-B29E-7C344D95F0E8Q33892330-49453489-049F-411F-8105-7FF8EAEAA35BQ34416848-FB7A7D7D-64CE-4F0D-9226-D96884F35EA4Q34606441-E6EF51BC-D81A-4EED-AF93-67D902393A36Q34609941-8A8F23AC-5653-430C-BB39-4F07BBF380EEQ34688159-4D69FC61-C45A-478A-AB37-A4BB1A583278Q34987426-D47AFBA6-5D40-43B6-8B81-F95E78474AB3Q35083375-4F1B08F7-B407-4414-98BB-FAE7CD00C7DDQ35088423-6CBECFE7-D01C-43BB-9E07-CD1CC540A219Q35120143-3CC2085A-4DCF-44D7-AC2F-071E76D2206BQ35141280-7DD4D03D-85A2-4D32-9819-E6FE8FE8F0A5Q35626057-7663A33D-2D9D-4E51-8934-3079FB9EAF64Q35740802-49F9789F-D2F3-4C6F-9ECE-029091A284AEQ35791948-5AFF3B99-1469-4F62-A1EE-B26F498F289CQ36040645-F4E202EE-D763-419E-943F-48F47F704148Q36156106-F953D884-315E-4F61-B71D-8309E0B12471Q36299503-90C8AC5B-6790-45B2-A1F3-6C180D127038Q36413548-A996C17A-957C-427E-97E7-E65503C4A2ABQ36421994-99A8E6E2-6207-4C9E-8B38-4A3BDD91212DQ36449089-4C81469D-70C3-46BE-BE5E-A17DC9265B89Q36820554-8302458E-89AA-4037-A9F1-9AC4FCB40EF8Q36882294-155EA5D3-073C-495E-80EB-D723211A123EQ36909572-D3263B15-4F74-4FF4-9C11-95F20FB380B7Q36990783-56C6F69D-84DB-48D5-825D-C7BAEA1605E1Q37053817-37DD24AB-5E78-4DBD-AEB4-B9B1176CA2B5Q37224663-A249C454-79BB-4B84-AD3B-DF61B6F50B88
P2860
Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Activation of c-Jun N-terminal ...... iated with amyloid deposition.
@en
Activation of c-Jun N-terminal ...... iated with amyloid deposition.
@nl
type
label
Activation of c-Jun N-terminal ...... iated with amyloid deposition.
@en
Activation of c-Jun N-terminal ...... iated with amyloid deposition.
@nl
prefLabel
Activation of c-Jun N-terminal ...... iated with amyloid deposition.
@en
Activation of c-Jun N-terminal ...... iated with amyloid deposition.
@nl
P2093
P1476
Activation of c-Jun N-terminal ...... ciated with amyloid deposition
@en
P2093
Dorothy G Flood
John R Ciallella
Mary J Savage
Richard W Scott
Yin-Guo Lin
P304
P356
10.1523/JNEUROSCI.22-09-03376.2002
P407
P577
2002-05-01T00:00:00Z